Welcome to our dedicated page for Surgery Partners SEC filings (Ticker: SGRY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medicare rate updates, shifting payor mixes and physician joint-venture agreements turn every Surgery Partners disclosure into a maze of acronyms and footnotes. If you have ever searched through a 300-page document just to learn which facilities drove same-store growth, you know the challenge. Stock Titan brings clarity by pairing each release with AI-powered summaries that translate reimbursement tables and regulatory language into plain English.
You will find every filing here as soon as it hits EDGAR: the Surgery Partners annual report 10-K simplified for long-term trends, each Surgery Partners quarterly earnings report 10-Q filing broken down into case-volume and payor-mix drivers, and every Surgery Partners 8-K material events explained so you see why management moved quickly. Need trading intel? Our dashboard tracks Surgery Partners insider trading Form 4 transactions and delivers Surgery Partners Form 4 insider transactions real-time. For governance questions, the Surgery Partners proxy statement executive compensation section highlights how physician leaders are paid. All documents come with concise, AI-generated key points so you can start understanding Surgery Partners SEC documents with AI instead of parsing line items yourself.
Use these insights to compare segment margins across facilities, monitor Surgery Partners executive stock transactions Form 4 before earnings, and follow guidance revisions the moment they appear. Whether you are preparing a model, monitoring covenant compliance, or simply looking for Surgery Partners earnings report filing analysis, our platform saves hours and ensures nothing slips past you.
Surgery Partners, Inc. (SGRY) Form 144 reports a proposed sale of 25,000 common shares to be executed on 09/23/2025 through UBS Financial Services (Weehawken, NJ). The filing states these shares were acquired on 09/23/2025 as equity compensation through an equity option exercise from Surgery Partners, Inc. The notice is submitted under Rule 144 and includes the seller's representation that they are not aware of any undisclosed material adverse information about the issuer. The filing also discloses numerous recent open-market sales by the same person, dated between 08/21/2025 and 09/22/2025, across multiple transactions.
Surgery Partners, Inc. (SGRY) Rule 144 notice discloses a proposed sale of 50,000 common shares through UBS Financial Services (Nasdaq) with an aggregate market value of $1,092,666 and an approximate sale date of 09/22/2025. The shares were acquired and paid for on 09/22/2025 via an equity option exercise from Surgery Partners, Inc. The filing also lists multiple recent open-market sales by Wayne DeVeydt totaling large share blocks between 08/21/2025 and 09/19/2025, including transactions of 100,000, 150,000, and other lots with combined gross proceeds in the multi-million dollar range. The filer affirms no undisclosed material adverse information.
Surgery Partners, Inc. (SGRY) Form 144 notice reports an intended sale of 10,613 common shares through UBS Financial Services on NASDAQ with an aggregate market value of $234,547.30. The securities were acquired the same day as equity compensation via an equity option exercise. The filer reports numerous recent open-market sales by Wayne DeVeydt totaling multiple transactions between August and September 2025, including sales of 100,000 and 150,000 share lots. The filing affirms the seller does not possess undisclosed material adverse information. The reported number of shares outstanding is 128,209,410, providing context for the relative scale of the transactions.
Surgery Partners, Inc. (SGRY) has submitted a Form 144 reporting a proposed sale of 150,000 common shares through UBS Financial Services with an aggregate market value of $3,294,454.97. The shares were acquired on 09/18/2025 via an equity option exercise from Surgery Partners, Inc., and the planned sale is listed for 09/18/2025 on NASDAQ. The filing also discloses multiple recent sales by Wayne DeVeydt between 08/21/2025 and 09/17/2025, including transactions of 100,000 shares on 08/21/2025 and 09/11/2025 and several smaller sales, each with stated gross proceeds. The notice includes the signers representation that they are not aware of undisclosed material adverse information about the issuer.
Surgery Partners, Inc. (SGRY) Form 144 reports a proposed sale of 85,785 common shares through UBS Financial Services with an aggregate market value of $1,873,875, with an approximate sale date of 09/17/2025 on NASDAQ. The shares were acquired on 09/17/2025 by equity compensation from Surgery Partners, Inc., with payment described as an equity option exercise. The filing also discloses multiple recent open-market sales by Wayne DeVeydt totaling 392,579 shares between 08/21/2025 and 09/16/2025 generating aggregate gross proceeds reported in the table. The signee represents no undisclosed material adverse information.
Surgery Partners, Inc. (SGRY) Form 144 shows a proposed sale of 25,000 common shares through UBS on 09/16/2025, with an aggregate market value reported as $541,517.60. The shares were acquired on 09/16/2025 via equity compensation and the payment/nature is listed as an equity option exercise. The filing also discloses that the same account (Wayne DeVeydt) sold a total of 367,579 common shares in the prior three months for aggregate gross proceeds of $8,267,200. The filing lists 128,209,410 shares outstanding, and the planned sale is to occur on the NASDAQ through UBS Financial Services.
Surgery Partners, Inc. (SGRY) Form 144 notice records a proposed sale of 100,000 shares of common stock through UBS Financial Services, scheduled approximately for 09/11/2025. The shares were acquired on 09/11/2025 via equity compensation (equity option exercise) from Surgery Partners, Inc. The filing reports the aggregate market value for the 100,000 shares as $2,201,000 and shows 128,209,410 shares outstanding. The filer also disclosed multiple recent sales by Wayne DeVeydt between 08/21/2025 and 09/08/2025, listing transaction sizes and gross proceeds for each sale. The notice includes the standard representations that the seller is not aware of any undisclosed material adverse information and that intentional misstatements are unlawful.
Surgery Partners, Inc. (SGRY) Form 144: The filing notifies a proposed sale of 2,014 common shares through UBS Financial Services with an aggregate market value of $45,217, to be sold on 09/08/2025. The shares were acquired the same day via equity compensation (equity option exercise) from Surgery Partners, Inc.
The filing also discloses prior sales by Wayne DeVeydt between 08/21/2025 and 09/05/2025 totaling 236,865 common shares for gross proceeds of $5,392,323. The form includes the mandatory representation that the seller is not aware of any undisclosed material adverse information.
Surgery Partners insider sale to cover tax withholding reduced holdings. National Group President Harrison R. Bane reported two stock sale transactions on 09/04/2025 at $22.48 per share, disposing of 5,726 and 3,613 shares respectively to satisfy tax withholding related to restricted stock vesting on 09/01/2025. After the sales, he beneficially owned 117,181 shares. The Form 4 was signed by an attorney-in-fact on 09/08/2025.
FAQ
What is the current stock price of Surgery Partners (SGRY)?
What is the market cap of Surgery Partners (SGRY)?
